Global Companion Diagnostics Market | Global Opportunities

1. Global Companion Diagnostics Market is Anticipated to Progress at a CAGR of 12.84% by 2028 Triton Market Research presents the Global Companion Diagnostics Market report segmented by Consumer (Reference Laboratories, Pharmaceutical and Biopharmaceutical Companies, Other Consumers), Mechanism (Polymerase Chain Reaction, Next Generation Sequencing, In-Situ Hybridization, Immunohistochemistry, Other Mechanisms), Indicator (Neurology, Oncology, Infectious Disease, Other Indicators), Commodity (Software & Services, Assay Kits & Reagents), and Regional Outlook (Europe, Asia-Pacific, North America, Latin America, Middle East and Africa). The report further discusses the Market Summary, Industry Outlook, Impact of COVID-19, Key Insights, Porter’s Five Forces Analysis, Market Attractiveness Index, Vendor Scorecard, Drivers, Challenges, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2022-2028). As per Triton’s research report, the global companion diagnostics market is estimated to witness growth at a CAGR of 12.84% during the forecast period 2022-2028. A companion diagnostics device helps attain crucial data to efficiently match a drug or therapy. It is a personalized treatment that includes drug testing, clinical trials, and research. Genome sequencing has emerged as a significant step in the gene therapy process. This has increased investments in next generation gene sequencing. Moreover, the rising research in the space is expected to promote the companion diagnostics market’s growth. Furthermore, the growing investments and research in precision medicine are also anticipated to elevate the demand for companion diagnostics tests, thereby opening new avenues for the studied market.

2. However, a weak reimbursement framework and common cases of leakage in oncology companion diagnostics restrict the companion diagnostics market’s growth. Globally, the Asia-Pacific is expected to emerge as the fastest-growing region over the forecast period. The region is witnessing growth owing to the increasing development of precision medicine technology. Moreover, an initiative undertaken by regulatory authorities and the pharmaceutical industry to increase precision medicine development drives the demand for companion diagnostics tests. Above all, the increase in healthcare awareness and economic growth are expected to open new avenues for the companion diagnostics market. Danaher Corporation, GE Healthcare, Roche Diagnostics, Arup Laboratories, Almac Group, Thermo Fisher Scientific, Genomic Health, Myriad Genetics, Illumina Inc, bioMerieux, Qiagen, Biocartis, Sysmex Corporation, Agilent, and Abbott Laboratories are leading companies in the companion diagnostics market. Companies in the market offer relatively similar products with small variations in terms of efficiency and capabilities. As a result, establishments are seeking to develop products with new features. The new entrants are required to invest a significant amount in order to adopt new technology and establish workstations. On the other hand, companies active in the market allocate significant resources, covering the majority of initial expenditures. Hence, these factors indicate the threat of new entrants to be medium.